WHO investigating links between cough syrup deaths, considers advice for
parents
Send a link to a friend
[January 24, 2023]
By Jennifer Rigby
(Reuters) -The World Health Organization (WHO) is investigating whether
there is any connection between manufacturers whose contaminated cough
syrups it has linked to the deaths of more than 300 children in three
countries, a person familiar with the matter told Reuters.
Citing “unacceptable levels” of toxins in the products, the WHO is
seeking more information about the specific raw materials used by six
manufacturers in India and Indonesia to produce medicines linked to the
recent deaths, as well as whether the companies obtained them from some
of the same suppliers, the person said. The WHO has not named any
suppliers.
The WHO also is considering whether to advise families globally to
reassess the use of cough syrups for children in general while questions
over the safety of some of these products are unresolved, the person
said. WHO experts are evaluating the evidence for whether, or when, such
products are medically necessary for children, the person said.
The deaths of children from acute kidney injury began in July 2022 in
Gambia, followed by cases in Indonesia and Uzbekistan. The WHO has said
the deaths are linked to over-the-counter cough syrups the children took
for common illnesses and which contained a known toxin, either
diethylene glycol or ethylene glycol.
To date, the WHO has identified six drugmakers in India and Indonesia
who produced the syrups. These manufacturers have either declined to
comment on the investigation or denied using contaminated materials that
contributed to any deaths. Reuters has no evidence of wrongdoing by the
companies the WHO has named.
“This is of the highest priority for us, to see no more child deaths
from something that is so preventable,” WHO spokesperson Margaret Harris
said, without commenting further on the details of the organisation's
work.
The United Nations health agency said on Monday it had widened its
investigation into potential diethylene glycol and ethylene glycol
contamination in cough syrups to four additional countries where the
same products may have been on sale: Cambodia, the Philippines, East
Timor and Senegal. It called on other governments and the global
pharmaceutical industry to launch urgent checks to root out substandard
medicines and improve regulation.
The International Federation of Pharmaceutical Manufacturers and
Associations (IFPMA) said in an emailed statement on Tuesday that its
members "are already doing what the WHO is calling for", in line with
national and international guidelines.
The WHO is expected to comment further on the cough syrup situation
during a news conference later on Tuesday.
The WHO has already issued specific alerts for cough syrups made by two
Indian manufacturers, Maiden Pharmaceuticals and Marion Biotech, in
October 2022 and earlier this month. It said their syrups were linked to
deaths in Gambia and Uzbekistan respectively, and the alerts asked
people to stop using them.
[to top of second column]
|
A logo is pictured at the World Health
Organisation (WHO) in Geneva, Switzerland, December 14, 2022.
REUTERS/Denis Balibouse
Maiden and Marion’s manufacturing
plants have both been shuttered. Maiden is now seeking to reopen
after the Indian government said in December that its testing had
found no problems with Maiden’s products.
Maiden has repeatedly told Reuters, including in December, that it
did nothing wrong and Managing Director Naresh Kumar Goyal said on
Tuesday he had no comment on WHO investigating possible connections
between the companies under scrutiny.
Marion’s office phone went unanswered on Tuesday and the company did
not immediately respond to an email seeking comment. Earlier this
month, it told the government of Uttar Pradesh, where it is located
near New Delhi, that it was being blamed for the deaths in
Uzbekistan “to malign the image of India and the company”.
The WHO, working with Indonesia’s drugs regulator, also issued an
alert in October about cough syrups made by four Indonesian
manufacturers and sold domestically. The manufacturers are: PT
Yarindo Farmatama, PT Universal Pharmaceutical, PT Konimex, PT AFI
Farma.
PT Yarindo Farmatama, PT Konimex and PT AFI Farma did not
immediately respond to requests for comment on Tuesday about the WHO
investigating connections between the deaths in the three countries.
PT Universal Pharmaceutical Industries’ lawyer, Hermansyah
Hutagalung, said it had pulled from the market all cough syrups
deemed dangerous. “Chase the suppliers, they’re the real criminals,”
Hutagalung added. “They’re the ones that forge raw ingredients by
falsifying raw ingredient documents all the way to pharmaceutical
companies.” He did not identify specific suppliers or give details
to back up the claim.
The WHO said the syrups were contaminated with diethylene glycol and
ethylene glycol, which it called “ toxic chemicals used as
industrial solvents and antifreeze agents that can be fatal even
taken in small amounts.” Their toxic effects include an inability to
pass urine, kidney injury and death.
The deaths have highlighted potential gaps in global regulation of
commonly-used medications, including oversight of factories and
supply chains, particularly those producing products for developing
countries which lack the resources to monitor medicines for safety.
The WHO sets guidelines on medicine manufacturing standards globally
and supports countries investigating any lapses, but it has no legal
mandate or enforcement authority to take direct action against
violators.
(Additional reporting by Prak Chan Thul in Phnom Penh, Stanley
Widianto and Ananda Teresia in Jakarta, Krishna N. Das in New Delhi,
Saurabh Sharma in Lucknow, Ed McAllister in Dakar; Editing by Sara
Ledwith, Michele Gershberg and Claudia Parsons)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |